Future adverse cardiac events can be predicted by persistently low plasma adiponectin concentrations in men and marked reductions of adiponectin in women after acute myocardial infarction

Kojima, Sunao; Funahashi, Tohru; Otsuka, Fumiyuki; Maruyoshi, Hidetomo; Yamashita, Takuro; Kajiwara, Ichiro; Shimomura, Hideki; Miyao, Yuji; Fujimoto, Kazuteru; Sugiyama, Seigo; Sakamoto, Tomohiro; Yoshimura, Michihiro; Ogawa, Hisao

doi:10.1016/j.atherosclerosis.2006.07.028

Cited by 59 publications

(43 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…29 Furthermore, a rapid decline in the adiponectin level following MI 30 and a persistently low level could be predictive of future adverse cardiac events in men following AMI. 31 More recently, our group investigated the association between plasma adiponectin level, and myocardial damage and function after successful reperfusion therapy in patients with AMI, as estimated by scintigraphy, and found that the plasma adiponectin level measured after coronary artery intervention could be an independent predictor of improvement of cardiac damage and function. 32 …”

Section: Ischemic Heart Diseasementioning

confidence: 99%

Adiponectin and Cardiovascular Disease

Shibata

Ouchi

Murohara

2009

Circ J

195

142

View full text Add to dashboard Cite

Obesity is strongly associated with metabolic and cardiovascular disorders. Adiponectin is an adipose-derived plasma protein that is downregulated in subjects with obesity-related disorders. Low levels of adiponectin are associated with the increased prevalence of obesity-linked cardiovascular diseases, including ischemic heart disease and peripheral artery disease. Experimental findings have shown that adiponectin has beneficial effects in the cardiovascular system by directly acting on the component cells of the heart and blood vessels. Adiponectin protects cardiovascular tissues under conditions of stress through a number of mechanisms: inhibition of pro-inflammatory and hypertrophic responses, and stimulation of endothelial cell responses. These effects of adiponectin are mainly attributed to the modulation of signaling molecules, including AMP-activated protein kinase. Thus, adiponectin could be a promising therapeutic target for cardiovascular diseases. (Circ J 2009; 73: 608 -614)

show abstract

Section: Ischemic Heart Diseasementioning

confidence: 99%

Adiponectin and Cardiovascular Disease

Shibata

Ouchi

Murohara

2009

Circ J

195

142

View full text Add to dashboard Cite

show abstract

“…26 It was shown that declining adiponectin levels after onset of AMI could be a positive predictor for future cardiac events. 27 Recently, we demonstrated that plasma adiponectin levels are associated positively with improvements in damaged myocardial tissue and function after successful reperfusion therapy in patients with AMI, as estimated by scintigraphic image analysis. 17 These data suggest that a therapeutic approach aimed at increasing adiponectin levels or its sensitivity to the heart could be useful for treating AMI.…”

Section: Discussionmentioning

confidence: 99%

Impact of a Single Intracoronary Administration of Adiponectin on Myocardial Ischemia/Reperfusion Injury in Pig Model

Shibata

Kondo

Ouchi

et al. 2009

Journal of Cardiac Failure

View full text Add to dashboard Cite

Background-Adiponectin plays a protective role in the development of obesity-linked disorders. We demonstrated that adiponectin exerts beneficial actions on acute ischemic injury in mice hearts. However, the effects of adiponectin treatment in large animals and its feasibility in clinical practice have not been investigated. This study investigated the effects of intracoronary administration of adiponectin on myocardial ischemia-reperfusion (I/R) injury in pigs.

show abstract

“…Therefore, hyperadiponectinemia as the result of renal insufficiency is accompanied by apparently unfavorable cardiovascular outcome. Paradoxically, APN has been widely implicated to exert protective effects on various cardiovascular disorders (13,20). In particular, low plasma APN levels in both healthy individuals and CKD patients are strongly associated with ischemic heart disease (3,17,38,40).…”

Section: Discussionmentioning

confidence: 99%

Increased myocardial ischemia-reperfusion injury in renal failure involves cardiac adiponectin signal deficiency

Song¹,

Yu²,

Zhang³

et al. 2014

American Journal of Physiology-Endocrinology and Metabolism

View full text Add to dashboard Cite

Tao L. Increased myocardial ischemiareperfusion injury in renal failure involves cardiac adiponectin signal deficiency. Am J Physiol Endocrinol Metab 306: E1055-E1064, 2014. First published March 4, 2014 doi:10.1152/ajpendo.00428.2013.-Plasma levels of adiponectin (APN) are significantly increased in patients with renal dysfunction and are inversely related to the risk of cardiovascular mortality. The present study was designed to determine the role of APN in myocardial ischemia-reperfusion (MI/R) injury in mice with renal failure and delineate the underlying mechanisms. Renal failure was induced by subtotal nephrectomy (SN). Human recombinant globular domain of adiponectin (gAd) or full-length adiponectin (fAd) was administered via intraperitoneal injection once daily for 7 consecutive days after SN, and in vivo MI/R was introduced 3 wk later. Both plasma and urinary levels of APN increased significantly in SN mice. Compared with sham-operated mice, cardiac function was significantly depressed, and myocardial infarct size and apoptosis increased in SN mice following MI/R. The aggravated MI/R injury was further intensified in APN-knockout mice and markedly ameliorated by treatment with gAd but not fAd. Moreover, SN increased myocardial NO metabolites, superoxide, and their cytotoxic reaction product peroxynitrite, upregulated inducible NO synthase expression, and decreased endothelial NOS phosphorylation. In addition, SN mice also exhibited reduced APN receptor-1 (AdipoR1) expression and AMPK activation. All these changes were further amplified in the absence of APN but reversed by gAd treatment. The present study demonstrates that renal dysfunction increases cardiac susceptibility to ischemic-reperfusion injury, which is associated with downregulated APN/AdipoR1/AMPK signaling and increased oxidative/nitrative stress in local myocardium, and provides the first evidence for the protective role of exogenous supplement of gAd on MI/R outcomes in renal failure. adiponectin; renal failure; subtotal nephrectomy; oxidative/nitrative stress CHRONIC KIDNEY DISEASE (CKD) is a major public health problem worldwide that has been repeatedly documented to be associated with increased risk for cardiovascular morbidity and mortality. It has been increasingly apparent that accelerated cardiovascular disease is prevalent in individuals with CKD and has become the leading complication of renal insufficiency. In particular, the incidence of acute myocardial infarction among patients with CKD is more than twice that of patients without CKD (28). Therefore, the prevention and treatment of cardiac insult are critical considerations in the management of individuals with CKD. Adiponectin (APN), a 30-kDa adipocyte-derived vasoactive peptide involved in the regulation of inflammation and energy metabolism, has shown beneficial effects on cardiovascular disorders (11). It is highly abundant in the circulation and exists as trimers, hexamers, or high-molecular-weight multimers (22). Hypoadiponenemia has been observed in individuals with i...

show abstract

Future adverse cardiac events can be predicted by persistently low plasma adiponectin concentrations in men and marked reductions of adiponectin in women after acute myocardial infarction

Cited by 59 publications

References 29 publications

Adiponectin and Cardiovascular Disease

Adiponectin and Cardiovascular Disease

Impact of a Single Intracoronary Administration of Adiponectin on Myocardial Ischemia/Reperfusion Injury in Pig Model

Increased myocardial ischemia-reperfusion injury in renal failure involves cardiac adiponectin signal deficiency

Contact Info

Product

Resources

About